HN2003000379A - Derivados de anilinopirazol utiles en el tratamiento de la diabetes - Google Patents
Derivados de anilinopirazol utiles en el tratamiento de la diabetesInfo
- Publication number
- HN2003000379A HN2003000379A HN2003000379A HN2003000379A HN2003000379A HN 2003000379 A HN2003000379 A HN 2003000379A HN 2003000379 A HN2003000379 A HN 2003000379A HN 2003000379 A HN2003000379 A HN 2003000379A HN 2003000379 A HN2003000379 A HN 2003000379A
- Authority
- HN
- Honduras
- Prior art keywords
- diabetes
- treatment
- anilinopirazol
- derivatives
- useful
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42991702P | 2002-11-27 | 2002-11-27 | |
| US49821403P | 2003-08-27 | 2003-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HN2003000379A true HN2003000379A (es) | 2005-12-20 |
Family
ID=32474531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HN2003000379A HN2003000379A (es) | 2002-11-27 | 2003-11-26 | Derivados de anilinopirazol utiles en el tratamiento de la diabetes |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7265144B2 (enExample) |
| EP (1) | EP1567517A1 (enExample) |
| JP (1) | JP2006510728A (enExample) |
| KR (1) | KR20050085170A (enExample) |
| AR (1) | AR042067A1 (enExample) |
| AU (2) | AU2003295890A1 (enExample) |
| BR (1) | BR0316723A (enExample) |
| CA (1) | CA2507186A1 (enExample) |
| HN (1) | HN2003000379A (enExample) |
| MX (1) | MXPA05004621A (enExample) |
| MY (1) | MY141528A (enExample) |
| PE (1) | PE20040907A1 (enExample) |
| PL (1) | PL377164A1 (enExample) |
| TW (1) | TW200418803A (enExample) |
| UY (1) | UY28098A1 (enExample) |
| WO (2) | WO2004050650A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2567352A1 (en) * | 2004-05-20 | 2005-12-01 | Bayer Pharmaceuticals Corporation | 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes |
| CA2602609A1 (en) * | 2005-03-16 | 2006-09-21 | Junichi Yokotani | Novel anthranilic acid derivative or salt thereof |
| MX2007016070A (es) * | 2005-07-07 | 2008-03-10 | Abbott Lab | Promotores de apoptosis. |
| CA2620425A1 (en) * | 2005-08-31 | 2007-03-08 | Bayer Healthcare Llc | Anilinopyrazole derivatives useful for the treatment of diabetes |
| WO2007129195A2 (en) * | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| US8022217B2 (en) | 2006-07-31 | 2011-09-20 | Cadila Healthcare Limited | Compounds suitable as modulators of HDL |
| CN103739595A (zh) | 2006-10-02 | 2014-04-23 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| EP2128138A1 (en) | 2007-01-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Pyrazole compound |
| US20110034521A1 (en) * | 2007-09-28 | 2011-02-10 | Alan Jacobson | Compounds and methods for treating zinc matrix metalloprotease dependent diseases |
| DE102008039083A1 (de) | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Aminopyrazole und ihre Verwendung |
| DE102008039082A1 (de) | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung |
| WO2010033360A1 (en) * | 2008-09-19 | 2010-03-25 | 1/3 Absolute Science, Inc. | Methods of treating a botulinum toxin related condition in a subject |
| BRPI0919248A2 (pt) | 2008-09-25 | 2019-09-24 | Hoffmann La Roche | derivados de 3-amino-indazol ou 3-amino-4,5,6,7-tetraidroindazol |
| AR075713A1 (es) | 2009-03-03 | 2011-04-20 | Du Pont | Pirazoles fungicidas |
| TWI504350B (zh) * | 2010-09-01 | 2015-10-21 | Du Pont | 殺真菌吡唑及其混合物 |
| TWI568721B (zh) | 2012-02-01 | 2017-02-01 | 杜邦股份有限公司 | 殺真菌之吡唑混合物 |
| US9630976B2 (en) | 2012-07-03 | 2017-04-25 | Ono Pharmaceutical Co., Ltd. | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes |
| CN103074693A (zh) * | 2013-01-18 | 2013-05-01 | 桐昆集团股份有限公司 | 带双导丝辊的poy纺丝卷绕装置 |
| WO2015100213A2 (en) | 2013-12-23 | 2015-07-02 | Amazentis Sa | Process-scale synthesis of urolithins |
| WO2016204270A1 (ja) * | 2015-06-18 | 2016-12-22 | 日本曹達株式会社 | ジアリールアゾール化合物および有害生物防除剤 |
| EP3632904B1 (en) * | 2017-05-26 | 2022-04-20 | Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. | Urat1 inhibitors for promoting uric acid excretion |
| WO2020227368A1 (en) * | 2019-05-08 | 2020-11-12 | Trustees Of Boston University | Hsp90 inhibitors and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL134200C (enExample) * | 1960-04-14 | |||
| US3790576A (en) * | 1972-03-20 | 1974-02-05 | Parke Davis & Co | 9 substituted 4,9-dihydro-1,3,4,4-tetraalkyl-1h-pyrazolo(3,4-b)quinolines |
| EP0586686A1 (en) | 1992-03-26 | 1994-03-16 | Dowelanco | N-heterocyclic nitro anilines as fungicides |
| EP0788358B1 (en) * | 1994-11-10 | 2004-03-31 | Millennium Pharmaceuticals, Inc. | Use of pyrazole compounds for the treatment of glomerulonephritis, cancer, atherosclerosis or restenosis |
| DE19532066A1 (de) | 1995-08-31 | 1997-03-06 | Bayer Ag | Substituierte 5-Aminopyrazole |
| FR2763334A1 (fr) * | 1997-05-13 | 1998-11-20 | Lipha | Derives anthraniliques |
| US5998424A (en) * | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
| US5942520A (en) * | 1998-01-27 | 1999-08-24 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines |
| ATE410415T1 (de) * | 2003-02-27 | 2008-10-15 | Smithkline Beecham Corp | Neue verbindungen |
-
2003
- 2003-11-18 AR ARP030104252A patent/AR042067A1/es unknown
- 2003-11-21 US US10/719,485 patent/US7265144B2/en not_active Expired - Fee Related
- 2003-11-21 AU AU2003295890A patent/AU2003295890A1/en not_active Abandoned
- 2003-11-21 WO PCT/US2003/037578 patent/WO2004050650A1/en not_active Ceased
- 2003-11-25 JP JP2004570952A patent/JP2006510728A/ja active Pending
- 2003-11-25 PL PL377164A patent/PL377164A1/pl not_active Application Discontinuation
- 2003-11-25 KR KR1020057009560A patent/KR20050085170A/ko not_active Withdrawn
- 2003-11-25 AU AU2003297565A patent/AU2003297565A1/en not_active Abandoned
- 2003-11-25 WO PCT/US2003/037829 patent/WO2004050651A1/en not_active Ceased
- 2003-11-25 CA CA002507186A patent/CA2507186A1/en not_active Abandoned
- 2003-11-25 MX MXPA05004621A patent/MXPA05004621A/es not_active Application Discontinuation
- 2003-11-25 BR BR0316723-2A patent/BR0316723A/pt not_active IP Right Cessation
- 2003-11-25 EP EP03812454A patent/EP1567517A1/en not_active Withdrawn
- 2003-11-26 PE PE2003001198A patent/PE20040907A1/es not_active Application Discontinuation
- 2003-11-26 TW TW092133242A patent/TW200418803A/zh unknown
- 2003-11-26 HN HN2003000379A patent/HN2003000379A/es unknown
- 2003-11-26 UY UY28098A patent/UY28098A1/es not_active Application Discontinuation
- 2003-11-27 MY MYPI20034545A patent/MY141528A/en unknown
-
2007
- 2007-08-31 US US11/897,620 patent/US20080064734A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004050651A1 (en) | 2004-06-17 |
| AU2003295890A1 (en) | 2004-06-23 |
| US20080064734A1 (en) | 2008-03-13 |
| US20040157904A1 (en) | 2004-08-12 |
| EP1567517A1 (en) | 2005-08-31 |
| PE20040907A1 (es) | 2005-01-27 |
| WO2004050650A1 (en) | 2004-06-17 |
| KR20050085170A (ko) | 2005-08-29 |
| US7265144B2 (en) | 2007-09-04 |
| AR042067A1 (es) | 2005-06-08 |
| TW200418803A (en) | 2004-10-01 |
| UY28098A1 (es) | 2004-06-30 |
| AU2003297565A1 (en) | 2004-06-23 |
| MXPA05004621A (es) | 2005-06-08 |
| BR0316723A (pt) | 2005-10-18 |
| CA2507186A1 (en) | 2004-06-17 |
| PL377164A1 (pl) | 2006-01-23 |
| JP2006510728A (ja) | 2006-03-30 |
| HK1087103A1 (zh) | 2006-10-06 |
| MY141528A (en) | 2010-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HN2003000379A (es) | Derivados de anilinopirazol utiles en el tratamiento de la diabetes | |
| UY28376A1 (es) | Agentes terapéuticos | |
| CR9954A (es) | Derivados de pirazina | |
| PA8586001A1 (es) | Derivados de indol útiles para el tratamiento de enfermedades | |
| UY28144A1 (es) | Agentes terapéuticos | |
| ECSP088099A (es) | Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas | |
| CR8649A (es) | Derivados de formamidina para el tratamiento de enfermedades | |
| PA8544901A1 (es) | Derivados de oxazol | |
| CR8858A (es) | Derivados de sulfamato y sulfamida para el tratamiento de epilepsia y trastornos relacionados | |
| ECSP088329A (es) | Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8 | |
| UY28215A1 (es) | Quinazolinas utiles como moduladores de canales iónicos | |
| UY31314A1 (es) | Amidas heterociclicas y sus métodos de uso-976 | |
| ECSP066972A (es) | Profármacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y métodos | |
| UY28774A1 (es) | Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes. | |
| CL2003002769A1 (es) | Compuestos derivados de carboxamida de tiazolilpirrol; procedimiento para su preparacion; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion de receptores canabinoid | |
| PA8621901A1 (es) | Derivados de sulfonamida para el tratamiento de enfermedades | |
| PA8604201A1 (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades | |
| UY31322A1 (es) | Amidas heterocíclicas y sus métodos de uso-975 | |
| PA8622401A1 (es) | Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico,procesos para su preparacion y su uso como medicamentos | |
| HN2008001666A (es) | Derivados acidos de cicloalquilamino | |
| DOP2005000025A (es) | Compuestos de heteroaril- y fenilsulfamoilo sustituidos | |
| UY29414A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| UY28377A1 (es) | Agentes terapeuticos | |
| ECSP088250A (es) | Derivados de pirazol como agentes terapéuticos | |
| UY28839A1 (es) | Agentes terapeuticos |